Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think! opens in new tab/window

Elsevier
Publish with us
AI-Generated response:

can diamox interact with hormonal birth control?

Answer generated on June 5, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

Diamox (acetazolamide) does not have documented interactions with hormonal contraceptives based on the provided sources.

  • Acetazolamide is primarily a carbonic anhydrase inhibitor and does not appear to induce or inhibit cytochrome P450 enzymes, which are commonly involved in drug interactions with hormonal contraceptives.[1]

  • Hormonal contraceptives' effectiveness can be diminished by drugs that induce certain liver enzymes (CYP3A4), but acetazolamide is not listed among these inducers.[2]

  • It is important to monitor for any unexpected symptoms or changes in menstrual bleeding patterns, as these could theoretically indicate an interaction not yet documented.

  • Regular follow-up and monitoring are advised to ensure the effectiveness of the contraceptive method and manage any potential side effects of either medication.

  • Patients should be counseled on using a consistent method of contraception and to report any irregularities in their menstrual cycle or symptoms suggestive of increased intracranial pressure.

Additional info

While there is no direct evidence of an interaction between acetazolamide and hormonal contraceptives, it remains crucial to monitor the patient closely due to the complexity of their medical condition and the potential for individual variability in drug metabolism and response. The physician should remain vigilant for any signs of contraceptive failure or exacerbation of idiopathic intracranial hypertension symptoms. Regular follow-ups would provide an opportunity to assess the treatment's effectiveness and safety, adjusting the therapeutic approach as necessary to optimize patient outcomes.

References

Reference 1

1.

Elsevier ClinicalKey Drug Monograph

Content last updated: March 4, 2024.

Interactions Diflunisal: (Moderate) The concomitant use of diflunisal and diamox has resulted in a significant decrease in intraocular pressure due to increased concentrations of diamox. If diflunisal and diamox are used concurrently, monitor the patient for signs and symptoms of toxicity; reduced drug dosages may be needed.

Interactions Fiasp: (Minor) Carbonic anhydrase inhibitors may alter blood sugar. Both hyperglycemia and hypoglycemia have been described in patients treated with diamox sequels. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus who are receiving antidiabetic agents. Monitor blood glucose and for changes in glycemic control and be alert for evidence of an interaction.

Interactions Isophane Insulin (NPH): (Minor) Carbonic anhydrase inhibitors may alter blood sugar. Both hyperglycemia and hypoglycemia have been described in patients treated with diamox sequels. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus who are receiving antidiabetic agents. Monitor blood glucose and for changes in glycemic control and be alert for evidence of an interaction.

Interactions Fiasp; Fiasp Protamine: (Minor) Carbonic anhydrase inhibitors may alter blood sugar. Both hyperglycemia and hypoglycemia have been described in patients treated with diamox. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus who are receiving antidiabetic agents. Monitor blood glucose and for changes in glycemic control and be alert for evidence of an interaction.

Reference 2

2.

Food and Drug Administration (DailyMed).

Publish date: February 3, 2019.

Precautions 8. Drug Interactions Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Effects of Other Drugs on Combined Hormonal Contraceptives Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of CHCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with CHCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.

Drug Interactions 8. Drug Interactions Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Effects of Other Drugs on Combined Hormonal Contraceptives Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of CHCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with CHCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Substances increasing the plasma concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.

Follow up questions